Boehringer Ingelheim (France)
University / College
Location:
Paris,
France (FR)
ISNI: 0000000405446220
ROR: https://ror.org/03gdpyq31
Show on Map:
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial (2019)
Highland K, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, et al.
Conference contribution
Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial (2019)
Mayes M, Highland K, Gahlemann M, Fischer A, Raghu G, Girard M, Alves M, et al.
Conference contribution